Patients should discontinue anti-platelet therapy at least 3 days before the injection procedure. Patients on anti-coagulant therapy need to be managed appropriately to decrease the risk of bleeding.

RADIESSE® is also used for correcting volume loss in the back of the hands. RADIESSE® (+) is also used for improving moderate to severe loss of jawline contour in adults over 21 years old.

Volume of reconstituted BOTOX and Diluent* (mL) to draw into dosing syringe to achieve a final volume of 10 mL

Subsequent injections should not be administered until the effects of the previous dose have dissipated as evidenced by substantial function in the injected and adjacent muscles.

Ask your doctor if you are not sure if your medicine is listed above. Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

This is because each manufacturer uses assay methods specific to their company, so even though dosages may be quoted in similar-sounding units, potency can vary several-fold between the different products. Care needs to be taken that the correct dosage stated is used for that particular product and the approved indications for the different products also vary.

Reinjection typically occurs once the benefits of the previous treatment have worn off, usually not more frequently than every 3 months.

Tell your health care provider if you are taking blood thinners or medicines that can interfere with the clotting of blood, such as aspirin or warfarin. These medicines might make it more likely that you will experience bruising or bleeding at the injection sitio.

If injection sites are marked in ink, do not inject BOTOX directly through the ink mark to avoid a permanent tattoo effect.

You should minimize strenuous activity and avoid extensive sun or heat exposure for about 24 hours after treatment and until any swelling or redness has resolved.

Xeomin and Botox both contain botulinum toxin type A, but each has distinctive characteristics that may benefit different patient populations. Xeomin's pure formulation without complexing proteins potentially botox offers advantages for long-term treatment and for patients concerned about developing resistance.

Clinical improvement generally begins within the first two weeks after injection with maximum clinical benefit at approximately six weeks post-injection. In the double-blind, placebo-controlled study most subjects were observed to have returned to pre-treatment status by 3 months post-treatment.

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

BOTOX is indicated for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.